SCHEMBL864170

SCHEMBL864170

CCCC(NC(=O)/C(C#N)=C/c1cccc(Cl)n1)c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP9X Q93008 10/20 0.78
UCHL1 P09936 1/20 0.78
USP5 P45974 1/20 0.78
STAT3 P40763 1/20 0.55
USP24 Q9UPU5 1/20 0.48
LMNA P02545 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
ITGA4 P13612 1/20 0.41
PKM P14618 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GPR35 Q9HC97 1/20 0.41
RCE1 Q9Y256 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
TACR3 P29371 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864169 1.00 USP9X (0.78) USP9XUCHL1USP5STAT3USP24
SCHEMBL864172 1.00 USP9X (0.78) USP9XUCHL1USP5STAT3USP24
SCHEMBL864171 1.00 USP9X (0.78) USP9XUCHL1USP5STAT3USP24
SCHEMBL1317671 0.88 USP9X (1.00) USP9XUCHL1USP5STAT3USP24
SCHEMBL13349344 0.88 USP9X (0.78) USP9XUCHL1USP5STAT3USP24
SCHEMBL864117 0.88 USP9X (0.78) USP9XUCHL1USP5STAT3USP24
SCHEMBL864116 0.88 USP9X (0.78) USP9XUCHL1USP5STAT3USP24
SCHEMBL1317674 0.88 USP9X (1.00) USP9XUCHL1USP5STAT3USP24
SCHEMBL1317669 0.88 USP9X (1.00) USP9XUCHL1USP5STAT3USP24
SCHEMBL864115 0.88 USP9X (0.78) USP9XUCHL1USP5STAT3USP24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619184-B1 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2018-05-23 EP disclosed
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UNIV MICHIGAN (US) 2014-12-04 US disclosed
US-8809377-B2 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-08-19 US disclosed
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 US disclosed
WO-2008005954-A2 TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UCHL1, USP2, USP1 USP9X 33/4885UCHL1 1/4885USP5 19/4885
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UCHL1, USP2, USP1 USP9X 33/4885UCHL1 1/4885USP5 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.